西藏易明西雅医药科技股份有限公司 2025 年半年度报告全文 西藏易明西雅医药科技股份有限公司 2025 年半年度报告 【2025 年 8 月】 1 西藏易明西雅医药科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人许可、主管会计工作负责人周敏及会计机构负责人(会计主管 人员)张永香声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，敬请投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异，注意投资风险。 本公司可能存在医药行业政策风险、管理风险、药品质量安全风险、单 一产品依赖风险，有关风险因素内容与对策举措已在本报告中第三节"管理 层讨论与分析"第十部分"公司面临的风险和应对措施"中予以描述，所涉 及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实际承诺， 请投资者注意投资 ...

天眼查商业履历信息显示，西藏易明西雅医药科技股份有限公司，成立于2007年，位于拉萨市，是一家 以从事批发业为主的企业。企业注册资本19067.775万人民币，实缴资本7491.4792万人民币。公司法定 代表人为许可。 通过天眼查大数据分析，西藏易明西雅医药科技股份有限公司共对外投资了6家企业，参与招投标项目 10次，知识产权方面有商标信息11条，专利信息16条，此外企业还拥有行政许可15个。 来源：金融界 金融界消息 截至2025年8月14日收盘，易明医药（002826）报收于23.5元，上涨5.33%，换手率 17.45%，成交量30.41万手，成交金额7.16亿元。 资金流向方面，今日主力资金净流入1.08亿元，占比成交额15.13%。其中，超大单净流入6231.90万 元、占成交额8.7%，大单净流入4605.43万元、占成交额6.43%，中单净流出流出1005.56万元、占成交 额1.4%，小单净流出9831.78万元、占成交额13.73%。 易明医药最新一期业绩显示，截至2025一季报，公司营业总收入1.49亿元、同比减少7.41%，归属净利 润1879.39万元，同比减少32.64%，扣非净利 ...

Group 1 - The core point of the article highlights that Yiming Pharmaceutical has seen a significant decrease in the number of shareholders, with a reduction of 3,379 accounts, representing a 14.94% decline compared to the previous period [2] - As of the latest report, Yiming Pharmaceutical's closing price was 22.31 yuan, reflecting a 3.00% decrease, although the stock price has increased by 2.81% since the concentration of shares began [2] - The company's Q1 financial report indicates a total revenue of 149 million yuan, a year-on-year decrease of 7.41%, and a net profit of 18.79 million yuan, down 32.64% year-on-year, with basic earnings per share at 0.1000 yuan and a weighted average return on equity of 2.51% [2]

来源：金融界 金融界8月13日消息，有投资者在互动平台向易明医药提问：贵公司股权转让事宜提交给证监会了吗？ 最近股价忽高忽低是否跟股权转让进展不顺利有关？是否业绩不太理想提前释放压力？截止到目前公司 十大股东持股有变化吗？ 公司回答表示：尊敬的投资者，您好。本次权益变动事项尚需取得深圳证券交易所的合规性确认意见并 在中国证券登记结算公司深圳分公司办理股份过户登记手续以及完成相关法律法规要求可能涉及的其他 批准，相关工作正在推进中，如有进展，将根据相关法规要求进行公告。公司将于2025年8月15日披露 2025年半年度报告，公司会根据规定在半年报中披露前十大股东持股情况，届时敬请关注。谢谢。 ...

金融界消息 截至2025年8月12日收盘，易明医药（002826）报收于23.0元，上涨0.83%，换手率 12.67%，成交量22.09万手，成交金额5.04亿元。 资金流向方面，今日主力资金净流入1188.00万元，占比成交额2.36%。其中，超大单净流出172.41万 元、占成交额0.34%，大单净流入1360.41万元、占成交额2.7%，中单净流出流出1655.32万元、占成交 额3.29%，小单净流入467.32万元、占成交额0.93%。 易明医药最新一期业绩显示，截至2025一季报，公司营业总收入1.49亿元、同比减少7.41%，归属净利 润1879.39万元，同比减少32.64%，扣非净利润1023.54万元，同比增长475.03%，流动比率2.781、速动 比率2.625、资产负债率22.20%。 天眼查商业履历信息显示，西藏易明西雅医药科技股份有限公司，成立于2007年，位于拉萨市，是一家 以从事批发业为主的企业。企业注册资本19067.775万人民币，实缴资本7491.4792万人民币。公司法定 代表人为许可。 通过天眼查大数据分析，西藏易明西雅医药科技股份有限公司共对外投资了6家企业，参 ...

证券之星消息，8月11日化学制药板块较上一交易日上涨1.29%，天宇股份领涨。当日上证指数报收于 3647.55，上涨0.34%。深证成指报收于11291.43，上涨1.46%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300702 | 天宇股份 | 29.77 | 14.50% | 26.66万 | | 7.87亿 | | 300436 | 广生堂 | 132.81 | 11.70% | 16.11万 | | 20.37亿 | | 603538 | 美诺华 | 28.68 | 10.01% | 51.47万 | | 14.26 乙 | | 002826 | 易明医药 | 22.81 | 9.98% | 19.74万 | | 4.38亿 | | 300255 | 常山药业 | 44.46 | 8.52% | 55.73万 | | 24.31亿 | | 300233 | 金城医药 | 19.14 | 7.65% | 57.97万 | | 10.9 ...

通过天眼查大数据分析，西藏易明西雅医药科技股份有限公司共对外投资了6家企业，参与招投标项目 10次，知识产权方面有商标信息11条，专利信息16条，此外企业还拥有行政许可15个。 金融界消息 截至2025年8月5日收盘，易明医药（002826）报收于21.34元，下跌3.09%，换手率7.74%， 成交量13.49万手，成交金额2.89亿元。 来源：金融界 易明医药最新一期业绩显示，截至2025一季报，公司营业总收入1.49亿元、同比减少7.41%，归属净利 润1879.39万元，同比减少32.64%，扣非净利润1023.54万元，同比增长475.03%，流动比率2.781、速动 比率2.625、资产负债率22.20%。 天眼查商业履历信息显示，西藏易明西雅医药科技股份有限公司，成立于2007年，位于拉萨市，是一家 以从事批发业为主的企业。企业注册资本19067.775万人民币，实缴资本7491.4792万人民币。公司法定 代表人为许可。 资金流向方面，今日主力资金净流出2334.51万元，占比成交额8.07%。其中，超大单净流出815.08万 元、占成交额2.82%，大单净流出1519.43万元、占成交额5. ...

New Stock Listings - HanGao Group listed on July 30, 2025, with an issue price of 15.43[1] - *ST Zitian and *ST Suwu are under severe abnormal fluctuations as of July 30, 2025[1] - Tianlu Convertible Bonds listed on July 30, 2025, with a risk warning[1] Market Alerts - Multiple stocks including *ST Xinchao and *ST Yuancheng are flagged for severe abnormal fluctuations on July 30, 2025[1] - New listings include companies like Xianghe Precision and Shenshui Planning, with announcements made on July 30, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1] Trading Insights - The report highlights the importance of monitoring newly listed stocks for potential volatility and investment opportunities[1] - Investors are advised to review the latest announcements and risk warnings associated with these stocks to make informed decisions[1]

Core Viewpoint - The announcement highlights the recent abnormal stock price fluctuations of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. and the ongoing changes in control due to a share transfer agreement with Beijing Fuhai [2][3][4]. Group 1: Stock Trading Abnormalities - The stock of Tibet Yiming Xiya Pharmaceutical experienced a cumulative price deviation of over 20% across three consecutive trading days on July 23, 24, and 25, 2025, indicating abnormal trading activity [3]. - The company confirmed that there were no undisclosed significant matters affecting the stock price and that the operational environment remains stable [4][5]. Group 2: Share Transfer Agreement - On May 31, 2025, a share transfer agreement was signed between the controlling shareholder Gao Fan and Beijing Fuhai, involving the transfer of 43,855,883 shares, which represents 23.00% of the total shares of the company [4]. - A supplementary agreement to the share transfer was signed on July 25, 2025, with further details disclosed in a subsequent announcement [2][4]. Group 3: Compliance and Future Reporting - The company is awaiting compliance confirmation from the Shenzhen Stock Exchange regarding the share transfer and must complete the necessary procedures for share registration [5]. - The company plans to disclose its 2025 semi-annual report on August 15, 2025, and is currently preparing the financial data [5].

Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., announced a significant change in control due to a share transfer agreement signed between the controlling shareholder Gao Fan and Beijing Fuhai, involving the transfer of 43,855,883 shares, which represents a substantial portion of the company's total shares [3][4]. - The company's stock experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 20% over three consecutive trading days from July 23 to July 25, 2025 [2]. - The board of directors confirmed that there are no undisclosed significant matters or ongoing negotiations that would require disclosure under the Shenzhen Stock Exchange regulations, ensuring transparency in the company's operations [4][5]. Group 2 - The company is currently in the process of preparing its semi-annual report, and as of now, it has not reached the threshold that would necessitate a performance forecast disclosure according to the Shenzhen Stock Exchange rules [5]. - The company will continue to adhere strictly to legal and regulatory requirements regarding information disclosure and will ensure timely updates to stakeholders [4].